Researchers at Penn's Abramson Cancer Center have molecularly engineered T-cells from patients with chronic lymphocytic leukemia and achieved an exceptional, unprecedented antitumor response. In the pilot study of three patients, two achieved complete remission and the third experienced remarkable antitumor response, which was impossible with previously available treatments. See original here: Genetically Modified T Cells Obliterate Chronic Lymphocytic Leukemia Tumors … Continue reading →

(June 1, 2010) Renee Reijo Pera, Ph.D., and Professor Michael Longaker discuss the future of regenerative medicine and the promise that stem cell research holds for this field. During the final quarter of the Stanford Mini Med School, some of the most timely and important topics in contemporary medicine and the biosciences are addressed. Stanford Mini Med School is a series arranged and directed by Stanford's School of Medicine and presented by the Stanford Continuing Studies program. See original here: Regenerative Medicine and Applications of Stem Cell Research … Continue reading →

Huntington's disease is an inherited neurodegenerative disorder that typically strikes in a person's thirties and leads to death about 10 to 15 years later. No effective therapy exists for the disease. Jan Nolta, director of the UC Davis Stem Cell Program and Institute for Regenerative Cures, has a CIRM Early Translational Award to develop stem cell-based therapies for Huntington's disease. Read more from the original source: Stem Cell Research: Huntington's Disease … Continue reading →